semaglutide and the heart protects beyond weight loss, SELECT trial shows Semaglutide Shows Secondary Cardiovascular Prevention

Brown, E., Cuthbertson, D

doi: 10.1016/j.neo.2017.09.002

This integrated model ensures consistent communication between providers and a unified treatment philosophy focused on achieving the patients long-term goals

In plain language, at least two-thirds of the cardiovascular protection is coming from something other than fat loss

Its promise, according to Dr Levi Garraway, PhD, Roches Chief Medical Officer and Head of Global Product Development, results from the robust weight loss combined with a well-tolerated safety profile. Furthermore, at the end of last year, Pfizer paid a $2 billion for China-based manufacturer YaoPharmas GLP-1 drug, increasing competition in the expanding market, while in August Teva secured US approval for a generic GLP-1 of its version of Novo Nordisks injectable Saxenda (liraglutide).